Slideshow

Toward Biomarker-Guided Treatment in Psychosis

Author(s):

Brian Miller, MD, PhD, MPH

Is oxidative stress a therapeutic target in schizophrenia?

Related Videos
Erin Crown, PA-C, CAQ-Psychiatry, and John M. Kane, MD, experts on schizophrenia
nicotine use
brain schizophrenia
schizophrenia
schizophrenia
exciting, brain
Related Content
FDA Committees Vote to Dismiss Clozapine REMS
November 20th 2024

FDA Committees Vote to Dismiss Clozapine REMS

Heidi Anne Duerr, MPH
Treating ‘Morally Objectionable’ Patients
September 27th 2021

Treating ‘Morally Objectionable’ Patients

James L. Knoll IV, MD
schizophrenia
November 18th 2024

Long-Acting Injectables and a Team-Driven Approach for Schizophrenia Treatment

Tracy Hicks, DNP, FNP/PMHNP-BC
More Than Postpartum Depression: Addressing Maternal Mental Health Through the Life Cycle
May 11th 2021

More Than Postpartum Depression: Addressing Maternal Mental Health Through the Life Cycle

Anita H. Clayton, MD
failed endpoint
November 11th 2024

Emraclidine for Schizophrenia Fails to Meet Primary Endpoints in Phase 2 EMPOWER Trials

Leah Kuntz
pharmacology
November 7th 2024

Schizophrenia Pharmacology: Version 2.0

John J. Miller, MD
© 2024 MJH Life Sciences

All rights reserved.